戻る
Tempus AI's PurIST® Algorithm Validated for Pancreatic Cancer Therapy Selection
戻る
株式ニュース
テーマ
Tempus AI's PurIST® Algorithm Validated for Pancreatic Cancer Therapy Selection
Tempus AI's PurIST® Algorithm Validated for Pancreatic Cancer Therapy Selection
Edgen Stock
·
Sep 13 2025, 03:25
共有先
共有先
リンクをコピー
ソース:
[1] Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
[2] TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape | Nasdaq
[3] TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape - Zacks